 |
|
|
 |
|
|
|
| " |
My husband,
George, recently had heart surgery and is on Coumadin. As a Sales Director, he travels
extensively and I can't tell you how grateful we are for your website. Before traveling
each week, he runs a list of your labs and maps. Instead of Coumadin being a major disruption,
it's a weekly appointment to schedule into his day wherever he is. Your informative site truly is a lifesaver!"
|
|
|
 |
|
|
|
|
Families like the Swigers appreciate having access
to our extensive national network of patient service
centers as well as to the wealth of information
available on our easy-to-navigate website.
We have grown principally through strategic
acquisitions and disciplined integrations. Now we
are leveraging our sales, service and science
expertise to accelerate organic growth and to
supplement acquired growth. For example, Quest
Diagnostics is a pioneer in online medical
transaction processing, including the electronic
transmission of test results and longitudinal data
on individual patients. Our innovative Care360
patient-centric physician portal lets your doctor
order lab tests and prescriptions online, streamline
administrative tasks (including patient eligibility
verification) and share clinical information with
referring doctors in a HIPAA-compliant way. Our
medical technology subsidiary, MedPlus, was
recognized by KLAS Enterprises as the number
one document management and imaging vendor
in 2004 for its ChartMaxx electronic patient
record system, which is used in hospitals.
We are in the forefront of offering new diagnostic
tests that can change the way doctors practice
medicine. Each year, we develop approximately
100 new and improved tests. We also collaborate
with others. Through a relationship with Johnson
& Johnson's Veridex unit, we offer an important
new test that measures the number of tumor cells
circulating in the blood of patients with metastatic
breast cancer. This test, called CellSearch,
enables physicians to individualize treatment
regimens for this group of women.
Early in 2005 we announced a collaboration with
The University of Texas M. D. Anderson Cancer
Center to develop new blood tests that one day
may eliminate the need for leukemia and lymphoma
patients to undergo often painful procedures to
obtain bone-marrow specimens. The new tests
we are developing also have the potential to give
doctors more clinically useful information than
they've had in the past to diagnose, treat and
monitor the treatment of these patients.
Many routine tests also continue to generate
growth. One of the fastest growth categories is
cardiovascular testing, including measures such
as cholesterol and triglycerides. Recent research
has shown the value of Cardio CRP, a measure
of inflammation, as an important independent
risk factor for heart attack even in patients with
"normal" cholesterol levels. Another promising
test that is gaining recognition is InSure, which
offers a patient-friendly alternative to unpleasant
and messy fecal occult blood testing, and has
been shown to improve patients' adherence
to recommended colorectal cancer screening
guidelines.
|
|
